

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

MERCK & CO., Inc.)	
)	
)	
Plaintiff,)	
)	
v.)	
)	
RANBAXY INC. and RANBAXY)	
LABORATORIES LIMITED,)	
)	
Defendant.)	
)	C.A. No. 07-229 (GMS)
RANBAXY INC. and RANBAXY)	
LABORATORIES LIMITED,)	
)	
Counterclaim Plaintiff,)	
)	
v.)	
)	
MERCK & CO., Inc.)	
)	
Counterclaim Defendant.)	
)	

**RANBAXY'S OPPOSITION TO MERCK'S MOTION FOR EXTENSION OF
TIME TO FILE ITS REPLY BRIEF IN SUPPORT OF ITS MOTION FOR
LEAVE TO FILE ITS FIRST SUPPLEMENTAL COMPLAINT**

Defendants Ranbaxy Inc. and Ranbaxy Laboratories Limited (collectively “Ranbaxy”), respectfully submit this opposition to Merck’s Motion for Extension of Time (D.I. 53). While Ranbaxy understands the Merck’s need for an extension to accommodate schedules, an extension of one week is not warranted in this instance.

First, the resolution of Merck’s Motion for Leave to File Its First Supplemental Complaint (D.I. 48) (the “Motion”), could be case dispositive and its outcome is likely to inform Ranbaxy’s business decisions related to the launch of its proposed product.

Accordingly, Ranbaxy would like briefing on the Motion to be completed as soon as possible so that the Motion is on the Court's docket and ready for consideration by the Court at the Court's convenience.

Second, Merck's Motion seeks to supplement its Complaint based on a Certificate of Correction issued by the PTO on November 6, 2007. Rather than file its Motion shortly after receiving the Certificate of Correction, Merck waited until the deadline for filing of motions to amend, knowing that the briefing schedule would likely overlap with the *Markman* hearing.

Given the importance to Ranbaxy of receiving a decision on the Motion and the fact that Merck self-selected the date of filing, Ranbaxy respectfully requests that Merck's Motion for Extension of Time be denied.

OF COUNSEL:

Mark Boland
 Kenneth J. Burchfiel
 Michael Dzwonczyk
 Chid S. Iyer
 Renita S. Rathinam
 Chandran B. Iyer
 Sughrue Mion PLLC
 2100 Pennsylvania Ave., N.W.
 Washington, D.C. 20037
 (202) 293-7060

Kelly E. Farnan
 Frederick D. Cottrell III (#2555)
 Cottrell @rlf.com
 Kelly E. Farnan (#4395)
 Farnan@rlf.com
 Richards, Layton & Finger
 One Rodney Square
 920 N. King Street
 Wilmington, DE 19899
Attorneys for Defendant/Counterclaimant
Ranbaxy Laboratories Limited and Ranbaxy
Inc.

Dated: February 6, 2008

UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on February 6, 2008, I electronically filed the foregoing document with the Clerk of Court using CM/ECF and caused the same to be served on the defendant at the addresses and in the manner indicated below:

HAND DELIVERY and E-MAIL:

Mary B. Graham
James W. Parrett, Jr.
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street
Wilmington, DE 19899

I hereby certify that on February 6, 2008, the foregoing document was sent to the following non-registered participants in the manner indicated:

E-MAIL:

Raymond N. Nimrod
Jenner & Block LLP
919 N. Third Avenue
37th Floor
New York, NY 10022-3908

Aaron A. Barlow
Gregory D. Bonifield
Jenner & Block LLP
330 N. Wabash Avenue
Chicago, IL 60611-7603

Kelly E. Farnan
Kelly E. Farnan (#4395)